Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

Silvia Novello; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; José Barrueco; Birgit Gaschler-Markefski; Ingolf Griebsch; Michael Palmer; Martin Reck

doi:10.1016/j.ejca.2014.11.015

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

European Journal of Cancer ◽

10.1016/j.ejca.2014.11.015 ◽

2015 ◽

Vol 51 (3) ◽

pp. 317-326 ◽

Cited By ~ 38

Author(s):

Silvia Novello ◽

Rolf Kaiser ◽

Anders Mellemgaard ◽

Jean-Yves Douillard ◽

Sergey Orlov ◽

...

Keyword(s):

Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Patient Reported ◽

Phase Iii Study

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30412-x ◽

2018 ◽

Vol 13 (4) ◽

pp. S80-S81 ◽

Cited By ~ 1

Author(s):

M. Perol ◽

S. Peters ◽

N. Pavlakis ◽

E. Levchenko ◽

M. Platania ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Patient Reported ◽

Phase Iii Study

Download Full-text

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology

Annals of Oncology ◽

10.1093/annonc/mdv343.04 ◽

2015 ◽

Vol 26 ◽

pp. vi74 ◽

Cited By ~ 1

Author(s):

P. Bidoli ◽

F. Cappuzzo ◽

A. Favaretto ◽

O. Alabiso ◽

M. Tiseo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Subgroup Analysis ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Lung Cancer ◽

10.1016/j.lungcan.2016.06.019 ◽

2016 ◽

Vol 99 ◽

pp. 94-101 ◽

Cited By ~ 7

Author(s):

Egbert F. Smit ◽

Yi-Long Wu ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Reply to “Letter to the Editor on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study’”, by V. C. G. Tjan-Heijnen, P. E. Postmus &A. Ardizzoni(Ann Oncol 2002; 13: 485–486)

Annals of Oncology ◽

10.1093/annonc/mdf139 ◽

2002 ◽

Vol 13 (3) ◽

pp. 486 ◽

Cited By ~ 1

Author(s):

P. Bunn

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Prophylactic Use

Download Full-text

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8046 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8046-8046 ◽

Cited By ~ 1

Author(s):

Egbert F. Smit ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

Ji Feng Feng ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study

Annals of Oncology ◽

10.1023/a:1012545507920 ◽

2001 ◽

Vol 12 (10) ◽

pp. 1359-1368 ◽

Cited By ~ 80

Author(s):

V.C.G. Tjan-Heijnen ◽

P.E. Postmus ◽

A. Ardizzoni ◽

Ch. Manegold ◽

J. Burghouts ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Prophylactic Use

Download Full-text

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.01.022 ◽

2017 ◽

Vol 12 (5) ◽

pp. 843-849 ◽

Cited By ~ 12

Author(s):

Maria Q. Baggstrom ◽

Mark A. Socinski ◽

Xiaofei F. Wang ◽

Lin Gu ◽

Thomas E. Stinchcombe ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Combination Chemotherapy ◽

Small Cell ◽

Phase Iii ◽

Advanced Stage ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Reply to the article “Editorial comment on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study’”, by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339–1340)

Annals of Oncology ◽

10.1093/annonc/mdf138 ◽

2002 ◽

Vol 13 (3) ◽

pp. 485-486 ◽

Cited By ~ 3

Author(s):

V.C.G. Tjan-Heijnen ◽

P.E. Postmus ◽

A. Ardizzoni

Keyword(s):

Lung Cancer ◽

Editorial Comment ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Prophylactic Use

Download Full-text

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase 2 Randomized, Double-Blind, Placebo-Controlled Studies

Clinical Lung Cancer ◽

10.1016/j.cllc.2021.03.010 ◽

2021 ◽

Author(s):

Jared Weiss ◽

Jerome Goldschmidt ◽

Zoran Andric ◽

Konstantin H. Dragnev ◽

Chad Gwaltney ◽

...

Keyword(s):

Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Three Phase ◽

Patient Reported ◽

Extensive Stage

Download Full-text